Dr. Thomas Gajewski, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Illinois College Of Medicine

  Medical School, 1991

• Defining the critical hurdles in cancer immunotherapy, 2011-12-14

• Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition, 2015-02-18

• High-throughput stability screening of neoantigen/HLA complexes improves immunogenicity predictions, 2018-11-13

• Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer, 2015-11-04

• Loss of PTEN promotes resistance to T cell-mediated immunotherapy, 2015-12-08

• Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advancedBRAFV600- mutated melanoma (BRIM7), 2014-05-06

• Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy), 2021-06-30

• Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance, 2018-08-21

• The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors, 2015-11-04

• Intratumoral CD8+T-Cell Apoptosis is a Major Component of T-Cell Dysfunction and Impedes Anti-Tumor Immunity, 2017-11-02

• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104), 2012-12-10

• Impact of oncogenic pathways on evasion of antitumour immune responses, 2018-01-12

• Epigenetic control of Cdkn2a.Arf protects tumor-infiltrating lymphocytes from metabolic exhaustion, 2020-10-01

• A Phase II Study of RO4929097 Gamma-Secretase Inhibitor in Metastatic Melanoma: SWOG 0933, 2014-09-23

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Relationship between Physician-Adjudicated Adverse Events and Patient-Reported Health-Related Quality of Life in a Phase II Clinical Trial (NCT01143402) of Patients with Metastatic Uveal Melanoma, 2016-12-05

• Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer, 2018-04-04

• WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia, 2018-01-11

• Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy), 2022-09-04

• Costimulatory and coinhibitory receptors in anti-tumor immunity, 2012-02-08

• Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction*, 2013-07-12

• Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment, 2015-11-04

• Chemokine Expression in Melanoma Metastases Associated with CD8+T-Cell Recruitment, 2009-03-17

• Effect of Selumetinib versus Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial, 2014-06-18

• Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial, 2016-06-21

• Type I IFN response and innate immune sensing of cancer, 2012-10-31

• Future perspectives in melanoma research: meeting report from the "Melanoma Bridge”, Napoli, December 5th-8th 2013, 2014-10-28

• STING pathway agonism as a cancer therapeutic, 2019-04-19

• The next hurdle in cancer immunotherapy: Overcoming the non-T cell-inflamed tumor microenvironment, 2015-06-03

• Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma, 2019-03-20

• Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy), 2019-07-22

• Glucose Deprivation Inhibits Multiple Key Gene Expression Events and Effector Functions in CD8+T Cells, 2010-10-19

• Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+T Cells, 2011-09-19

• Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer, 2015-09-15

• Exploring the emerging role of the microbiome in cancer immunotherapy, 2019-04-17

• Review of the 25thannual scientific meeting of the International Society for Biological Therapy of Cancer, 2011-05-12

• STING-dependent Cytosolic DNA Sensing Promotes Radiation-induced Type I interferon-dependent Antitumor Immunity in Immunogenic Tumors, 2014-11-06

• Novel Response to Neoadjuvant Anti-PD1 Therapy for a Patient with Retrocaval Melanotic Schwannoma, 2021-02-01

• ß-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells-Phospholipase C-?1 Phosphorylation, 2010-12-13

• Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics, 2015-11-04

• The STING pathway and the T cell-inflamed tumor microenvironment, 2015-03-07

• WNT/ß-catenin pathway activation correlates with immune exclusion across human cancers, 2019-01-11

• Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy), 2023-07-28

• The microbiota: a new variable impacting cancer treatment outcomes, 2017-04-26

• CommensalBifidobacteriumpromotes antitumor immunity and facilitates anti-PD-L1 efficacy, 2015-11-05

• T cell-NF-?B activation is required for tumor controlin vivo, 2015-01-20

• A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma, 2013-06-27

• Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy, 2013-03-30

• Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting, 2013-05-29

• Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma, 2019-11-08

• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+T cells directly within the tumor microenvironment, 2014-02-18

• A new paradigm for tumor immune escape: ß-catenin-driven immune exclusion, 2015-09-15

• Melanoma and immunotherapy bridge 2015 Naples, Italy. 1-5 December 2015, 2016-07-25

• Sensitive detection and quantification of SARS-CoV-2 in saliva, 2021-06-14

• Antagonism of the STING pathway via activation of the AIM2 inflammasome by intracellular DNA, 2016-02-29

• Brain Tumor Micro-Environment and Host State - Implications for Immunotherapy, 2019-02-25

• Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011, 2012-05-28

• Future perspectives in melanoma research: meeting report from the "Melanoma Bridge”: Napoli, December 3rd-6th 2014, 2015-11-30

• Innate immune sensing of a growing tumor in vivo occurs via the host sting pathway and involves mitochondrial DNA transfer from cancer cells to DCs, 2013-11-07

• Phase 1 Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients, 2012-08-07

• Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab, 2018-07-16

• Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction, 2021-11-24

• Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting, 2016-12-01

• Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts, 2018-01-15

• First-in-Human Phase 1 Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies, 2017-01-04

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation*, 2012-02-06

• Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma, 2014-11-12

• Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity, 2015-05-07

• Up-Regulation of PD-L1, IDO, and Tregsin the Melanoma Tumor Microenvironment Is Driven by CD8+T Cells, 2013-08-28

• Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib inBRAF-Mutant Melanoma, 2019-11-15

• Cancer Immunotherapy, 2012-01-08

• SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery, 2011-09-19

• Phase II Study of the Src Kinase Inhibitor Saracatinib (AZD0530) in Metastatic Melanoma, 2012-11-15

• Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy, 2015-08-24

• Cancer classification using the Immunoscore: a worldwide task force, 2012-10-03

• Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012”, 2013-06-03

• Primary Murine CD4+T Cells Fail to Acquire the Ability to Produce Effector Cytokines When Active Ras Is Present during Th1/Th2 Differentiation, 2014-11-14

• Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers, 2015-11-04

• Molecular Drivers of the Non-T Cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer, 2016-05-17

• Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, 2017-10-12

• Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo, 2013-11-07

• Perspectives in melanoma: meeting report from the "Melanoma Bridge” (December 5th-7th, 2019, Naples, Italy), 2020-09-07

• Engineering Active IKKß in T Cells Drives Tumor Rejection1, 2016-02-22

• Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses, 2014-01-13

• A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors, 2018-06-09

• LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control, 2015-11-04

• STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors, 2014-11-05

• FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6th2011”, 2012-07-04

• Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells, 2020-01-30

• Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma, 2015-11-04

• The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, 2018-01-05